VLS Valneva SE

VALNEVA - Declaration of shares and voting rights: October 31, 2024

VALNEVA - Declaration of shares and voting rights: October 31, 2024

VALNEVA

Declaration of shares and voting rights

October 31, 2024

__________________________________________________________________________________________

Company name: VALNEVA

Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)

Regulated market of Euronext Paris - Compartment B

Declaration date: November 6, 2024

Number of shares

composing the share capital of Valneva
Total number of voting rights including suspended voting rights*Description of the change Date on which this change was recognizedTotal number of voting rights excluding suspended voting rights**
 



162,494,003



 



ordinary shares with a par value of €0.15 each
178,365,675Transfer into bearer form of 208 shares with double voting rights



 



Definitive attribution of 217,102 free ordinary shares



 



Double voting rights granted on 4,050 ordinary shares
Between October 8 & 10, 2024



 



October 10, 2024



 



Between October 6 & 31, 2024
178,241,353

___________________________

* Theoretical voting rights. This number is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

** Net (or exercisable at a General Meeting) voting rights.

Attachment



EN
06/11/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Valneva SE

 PRESS RELEASE

Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vac...

Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S. Saint Herblain (France), August 25, 2025 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the United States Food and Drug Administration (FDA) has suspended the license for IXCHIQ®, citing four new reports of serious adverse events (SAEs) consistent with chikungunya-like illness. The suspension of the license is effective immediately and requires Valneva to stop shipping and selling of IXCHIQ® in the United States. The suspension follows the FDA’s decisio...

 PRESS RELEASE

Valneva annonce la décision de la FDA de suspendre la licence d’IXCHIQ...

Valneva annonce la décision de la FDA de suspendre la licence d’IXCHIQ® aux États-Unis Saint Herblain (France), le 25 août, 2025 – (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui que l’agence de santé américaine Food and Drug Administration (FDA) a suspendu la licence d’IXCHIQ®, citant quatre nouveaux cas d’effets indésirables graves s’apparentant à la maladie provoquée par le chikungunya. Cette suspension entre en vigueur immédiatement et implique une interruption de l’envoi et de la vente d’IXCHIQ® aux États-Unis. Cette suspension fait su...

 PRESS RELEASE

Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Ind...

Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older Saint Herblain (France), August 18, 2025 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that Health Canada has granted marketing authorization for its single-dose vaccine, IXCHIQ®, for the prevention of disease caused by the chikungunya virus in individuals aged 12 years and older. This announcement adds to the adult marketing authorization already received in Canada1 and complements the adolescent label extension received in Europe in April 20252. In addit...

 PRESS RELEASE

Le vaccin IXCHIQ® de Valneva contre le chikungunya désormais autorisé ...

Le vaccin IXCHIQ® de Valneva contre le chikungunya désormais autorisé au Canada pour les personnes âgées de 12 ans et plus Saint-Herblain (France), le 18 août 2025 – (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que Santé Canada a accordé une autorisation de mise sur le marché pour son vaccin à dose unique, IXCHIQ®, pour la prévention de la maladie causée par le virus du chikungunya chez les personnes âgées de 12 ans et plus. Cette annonce s'ajoute à l'autorisation de mise sur le marché déjà obtenue au Canada pour les adultes1 et fait...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch